Why the study?
Pulmonary arterial hypertension causes impaired quality of life and survival, but there are limited data and no guidelines regarding the timing of palliative care referral in these patients.
Does palliative care improve quality of life and symptom management in patients with pulmonary arterial hypertension?
Does palliative care improve quality of life and symptom management in patients with pulmonary arterial hypertension?
Incorporation of palliative care in the longitudinal management of pulmonary arterial hypertension may be beneficial to address the multidimensional aspects of living with a chronic and life-limiting illness.
PC integration may ease symptom burden in advanced PAH; leaves open optimal timing and referral impact in this population.
Background Pulmonary arterial hypertension (PAH) is a chronic and progressive disease associated with impaired health-related quality of life and survival. Palliative care (PC) is patient- and family-centered care provided by an interdisciplinary team with an overarching goal of alleviating suffering and improving quality of life for patients with advanced illness. PC in other chronic diseases is associated with improved quality of life, symptom management, illness understanding, and reduced caregiver burden, but there is limited data regarding PC in PAH. Despite limited evidence, there is strong rationale for involving PC specialists in the longitudinal management of PAH. Implications for Clinicians There are currently no guidelines to help clinicians determine the most appropriate timing for referral of PAH patients to PC specialty teams. Consequently, referrals are limited and often delayed. Adoption of a standardized approach to PC referrals based on clinical or patient triggers could facilitate earlier involvement of PC as an adjunct to ongoing PAH disease-directed care. Conclusions Incorporation of PC in the longitudinal management of PAH may be beneficial to address the multidimensional aspects of living with a chronic and life-limiting illness.
No takes yet. Share an insight, caveat, or question.
Rhee et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Advances in Pulmonary Hypertension